The ICF syndrome protein CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of a non-B DNA
Science Advances · 2024
DOI: 10.1126/sciadv.adr0036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Swanand Hardikar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Primary Immunodeficiency Diseases, DNA Methylation, CpG Islands, Protein Binding. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
CDCA7 , encoding a protein with a carboxyl-terminal cysteine-rich domain (CRD), is mutated in immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome, a disease related to hypomethylation of juxtacentromeric satellite DNA. How CDCA7 directs DNA methylation to juxtacentromeric regions is unknown. Here, we show that the CDCA7 CRD adopts a unique zinc-binding structure that recognizes a CpG dyad in a non-B DNA formed by two sequence motifs. CDCA7, but not ICF mutants, preferentially binds the non-B DNA with strand-specific CpG hemi-methylation. The unmethylated sequence motif is highly enriched at centromeres of human chromosomes, whereas the methylated motif is distributed throughout the genome. At S phase, CDCA7, but not ICF mutants, is concentrated in constitutive heterochromatin foci, and the formation of such foci can be inhibited by exogenous hemi-methylated non-B DNA bound by the CRD. Binding of the non-B DNA formed in juxtacentromeric regions during DNA replication provides a mechanism by which CDCA7 controls the specificity of DNA methylation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Program in Genetics and Epigenetics, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
ORCID-Profile: Swanand Hardikar, Ren Ren, Zhengzhou Ying, Jujun Zhou, John R Horton, Matthew D Bramble, Jiameng Dan, Xiaodong Cheng, Taiping Chen
Förderung
- NIGMS NIH HHS
Zitieren
APA
Hardikar, S., Ren, R., Ying, Z., Zhou, J., Horton, J. R., Bramble, M. D., Liu, B., Lu, Y., Liu, B., Coletta, L. D., Shen, J., Dan, J., Zhang, X., Cheng, X., & Chen, T. (2024). The ICF syndrome protein CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of a non-B DNA. Science Advances. https://doi.org/10.1126/sciadv.adr0036
Vancouver
Hardikar S, Ren R, Ying Z, Zhou J, Horton JR, Bramble MD, et al. The ICF syndrome protein CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of a non-B DNA. Science Advances. 2024. doi:10.1126/sciadv.adr0036
BibTeX
@article{Hardikar2024,
author = {Hardikar, Swanand and Ren, Ren and Ying, Zhengzhou and Zhou, Jujun and Horton, John R and Bramble, Matthew D and Liu, Bin and Lu, Yue and Liu, Bigang and Coletta, Luis Della and Shen, Jianjun and Dan, Jiameng and Zhang, Xing and Cheng, Xiaodong and Chen, Taiping},
title = {The ICF syndrome protein CDCA7 harbors a unique DNA binding domain that recognizes a CpG dyad in the context of a non-B DNA},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adr0036}
}
EUVIMED